Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $5.74 Analyst target: $19.64 Upside: 242.16%
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.